University of Cincinnati-ko ikertzaileekin lankidetzan egindako argitalpenak (18)

2023

  1. Abnormal physiological findings after FFR-based revascularisation deferral are associated with worse prognosis in women

    Scientific Reports, Vol. 13, Núm. 1

  2. Changes in microvascular resistance following percutaneous coronary intervention - From the ILIAS global registry

    International Journal of Cardiology, Vol. 392

  3. Combined use of hyperemic and non-hyperemic pressure ratios for revascularization decision-making: From the ILIAS registry

    International Journal of Cardiology, Vol. 370, pp. 105-111

  4. Microvascular resistance reserve: diagnostic and prognostic performance in the ILIAS registry

    European heart journal, Vol. 44, Núm. 30, pp. 2862-2869

  5. Prognostic Implications of Individual and Combinations of Resting and Hyperemic Coronary Pressure and Flow Parameters

    JACC: Asia, Vol. 3, Núm. 6, pp. 865-877

  6. Sex differences in prevalence and outcomes of the different endotypes of chronic coronary syndrome in symptomatic patients undergoing invasive coronary angiography: Insights from the global ILIAS invasive coronary physiology registry

    Atherosclerosis, Vol. 384

2022

  1. Clinical Relevance of Ischemia with Nonobstructive Coronary Arteries According to Coronary Microvascular Dysfunction

    Journal of the American Heart Association, Vol. 11, Núm. 9

  2. Combined Assessment of FFR and CFR for Decision Making in Coronary Revascularization: From the Multicenter International ILIAS Registry

    JACC: Cardiovascular Interventions, Vol. 15, Núm. 10, pp. 1047-1056

  3. Differential Impact of Coronary Revascularization on Long-Term Clinical Outcome According to Coronary Flow Characteristics: Analysis of the International ILIAS Registry

    Circulation. Cardiovascular interventions, Vol. 15, Núm. 6, pp. e011948

  4. Differential Prognostic Value of Revascularization for Coronary Stenosis With Intermediate FFR by Coronary Flow Reserve

    JACC: Cardiovascular Interventions, Vol. 15, Núm. 10, pp. 1033-1043

  5. ISARIC-COVID-19 dataset: A Prospective, Standardized, Global Dataset of Patients Hospitalized with COVID-19

    Scientific Data, Vol. 9, Núm. 1

  6. Prognostic value of structural and functional coronary microvascular dysfunction in patients with non-obstructive coronary artery disease; from the multicentre international ILIAS registry

    EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology, Vol. 18, Núm. 9, pp. 719-728

2021

  1. Cardiovascular Risk and Health Among People With Human Immunodeficiency Virus (HIV) Eligible for Primary Prevention: Insights From the REPRIEVE Trial

    Clinical Infectious Diseases, Vol. 73, Núm. 11, pp. 2009-2022

2020

  1. MiR130b from Schlafen4 + MDSCs stimulates epithelial proliferation and correlates with preneoplastic changes prior to gastric cancer

    Gut, Vol. 69, Núm. 10, pp. 1750-1761

2018

  1. A phase Ib/II study (SCORES) of durvalumab (D) plus danvatirsen (DAN; AZD9150) or AZD5069 (CX2i) in advanced solid malignancies and recurrent/metastatic head and neck squamous cell carcinoma (RM-HNSCC): Updated results

    Annals of oncology : official journal of the European Society for Medical Oncology, Vol. 29, pp. viii372

2016

  1. The 2015 International Society for Heart and Lung Transplantation Guidelines for the management of fungal infections in mechanical circulatory support and cardiothoracic organ transplant recipients: Executive summary

    Journal of Heart and Lung Transplantation

2007

  1. Short-term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure: The EVEREST clinical status trials

    Journal of the American Medical Association, Vol. 297, Núm. 12, pp. 1332-1343

2005

  1. Rationale and design of the multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy of vasopressin antagonism in heart failure: Outcome study with Tolvaptan (EVEREST)

    Journal of Cardiac Failure, Vol. 11, Núm. 4, pp. 260-269